The patient perspective

PREFER looks at how and when it is best to perform and include patient-preference in decision making during the drug life cycle. We include patient stakeholders at every level of the project. The end-result will be recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies.

  • Why do we need a Public-Private partnership?

  • Giving patients a voice in drug development

  • What is a patient preference?

  • Whose preferences are we collecting?

Finding out what patients prefer

Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when and where patients want, can, and should be involved in drug development.

We are looking forward to sharing our findings with you!

Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader

Mats G. Hansson, co-ordinator & Conny Berlin, project leader, PREFER